A growing number of Americans are clamoring for Ozempic and Wegovy to lose weight. Now an even more powerful obesity medicine is poised to upend treatment.
If approved for weight loss, tirzepatide could become the most effective drug to date in an arsenal of medications that are transforming the treatment of obesity, which affects more than 4 in 10 American adults and is linked to dozens of diseases that can lead to disability or death.
Mounjaro was first approved to treat diabetes last year. Since then, thousands of patients have obtained the drug from doctors and telehealth providers who prescribed it “off-label” to help them slim down. “They have entirely changed the landscape,” said Dr. Amy Rothberg, a University of Michigan endocrinologist who directs a virtual weight loss and diabetes program.
Ozempic and Wegovy are two versions of semaglutide. That drug mimics a key gut hormone, known as GLP-1, that is activated after people eat, boosting the release of insulin and slowing release of sugar from the liver. It delays digestion and reduces appetite, making people feel full longer.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly stock up premarket as company’s Q1 revenue beats and it raises guidanceEli Lilly & Co. shares rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance....
Read more »
Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Read more »
Supply of prostate cancer drug should increase later this year, drugmaker saysSupply of cancer drug Pluvicto should increase in second half of the year, company says
Read more »
Bristol-Myers CEO Giovanni Caforio to Leave DrugmakerChief Commercialization Officer Christopher Boerner to take over after Giovanni Caforio retires, the company said.
Read more »
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO saysBiogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.
Read more »
Rep. Eli Crane rips federal agency over tribal mine delaysRep. Eli Crane wrote to Interior Secretary Deb Haaland to encourage the feds to cut red tape holding up the tribe's mines.
Read more »